Simeprevir with peginterferon α-2a/ribavirin for chronic hepatitis C virus genotype 1 infection in treatment-experienced patients: an open-label, rollover study

BMC Infectious Diseases

卷:17

Stefan Bourgeois¹  Henk Reesink²  Peter Ferenci³  Moises Diago⁴  Igor Nikitin⁵  Oliver Lenz⁶  Wolfgang Jessner⁶  Chris Corbett⁶  Maria Beumont⁶  Bart Fevery⁶  Ronald Kalmeijer⁷  Umesh Shukla⁷  Holger Hinrichsen⁸  Edward J. Gane⁹  Edwin DeJesus¹⁰  Ewa Janczewska¹¹  Mariliza Hendrique Da Silva¹²  Jacob George¹³ 

[1] ;

[2] Academic Medical Center;

[3] Allgemeines Krankenhaus der Stadt Wien, Universitätsklinik für Innere Medizin III;

[4] Hospital Quiron De Valencia;

[5] Institution of Russian Academy of Sciences Central Clinical Hospital;

[6] Janssen Pharmaceutica NV;

[7] Janssen Research & Development, LLC;

[8] Leberstudienzentrum Kiel GbR;

[9] New Zealand Liver Transplant Unit, Auckland City Hospital;

[10] Orlando Immunology Center;

[11] Outpatients Clinic for Hepatology, ID Clinic;

[12] Reference and Training Center IST/AIDS – State Program of São Paulo;

[13] Storr Liver Centre, Westmead Institute for Medical Research, Westmead Hospital and University of Sydney;

关键词: Chronic hepatitis C;    Direct-acting antiviral therapy;    Peginterferon;    Ribavirin;    Safety;    Simeprevir;   

DOI  :  10.1186/s12879-017-2444-3

来源: DOAJ

【 摘 要 】

Abstract Background This Phase 3, open-label, rollover study (NCT01323244) investigated the efficacy and safety of simeprevir plus peginterferon α-2a (PegIFNα-2a) and ribavirin (RBV) in a well-characterized population of HCV genotype 1 (GT1)-infected treatment-experienced patients. Methods Patients who had failed PegIFNα/RBV treatment in the placebo arm of a previous Phase 2/3 simeprevir study (Phase 2/3 group, n = 125), or had been exposed to HCV direct-acting antivirals (simeprevir or other) for up to 14 days in a selected Phase 1 study (Phase 1 group, n = 16), were eligible. Phase 2/3 group patients were classified according to prior relapse, breakthrough, or non-response (null response, partial response, non-classifiable non-response) to PegIFNα/RBV. Eight patients in the Phase 1 group received short-term (≤14 days) simeprevir. Treatment comprised simeprevir 150 mg once daily (QD) plus PegIFNα-2a/RBV for 12 weeks followed by PegIFNα-2a/RBV for 12 or 36 weeks (using response-guided therapy [RGT] to determine total treatment duration in Phase 2/3 prior relapsers or breakthrough) or 36 weeks fixed (Phase 2/3 group non-responders and Phase 1 group). The primary endpoint was sustained virologic response 12 weeks after planned end of treatment (SVR12). Results Phase 2/3 group: SVR12 rate was 69.6% (87/125) overall; 92.7% (51/55), 60.0% (6/10), 64.3% (18/28), and 36.7% (11/30) in patients with prior relapse, viral breakthrough, partial response, or null response, respectively. SVR12 rates were similar for patients with HCV GT1a (66.0% [33/50]) and GT1b infection (72.0% [54/75]) and among HCV GT1a-infected patients with/without a baseline Q80K polymorphism (66.7% [8/12] and 65.8% [25/38], respectively). The majority of RGT-eligible patients (prior viral relapse or breakthrough) met RGT criteria (89.2% [58/65]); of these, 89.7% (52/58) achieved SVR12. Overall, 16.0% (20/125) of patients experienced on-treatment failure and 14.4% (18/125) experienced post-treatment failure (15 relapses, 3 missing data). Phase 1 group (simeprevir-naïve and -experienced patients combined): SVR12 rate was 37.5% (6/16). Safety and tolerability findings were comparable to those of the feeder studies. Conclusions The majority of RGT-eligible patients met criteria for shortening treatment to 24 weeks in total. Simeprevir 150 mg QD with PegIFNα-2a/RBV led to a high SVR rate among prior relapsers with HCV GT1 infection. No new safety signals were noted. Trial registration NCT01323244 . (date of registration: March 24, 2011).

【 授权许可】

Unknown